Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-structural protein 1 (NS1) is a highly conserved glycoprotein encoded by flaviviruses, including dengue, Zika, yellow fever, West Nile, and Japanese encephalitis viruses. It consists of 352 amino acids and exists in multiple forms: intracellular dimeric NS1 (involved in genome replication and assembly), membrane-associated NS1 (cell surface), and secreted hexameric NS1 (mediates immune evasion and endothelial dysfunction). NS1 does not form part of the virion structure but is crucial for viral replication, virion maturation, and pathogenesis—contributing to immune evasion by binding complement proteins, disrupting the glycocalyx of endothelial cells, and supporting viral immune escape. NS1 is an important diagnostic biomarker (especially for dengue), and a promising but challenging therapeutic target for antiviral drugs and vaccines aimed at preventing severe flavivirus infections[1][2][3][5].
Drugs (such as antibodies or vaccines) targeting NS1 aim to neutralize its immune evasion function, block its role in endothelial dysfunction, and prevent viral replication and dissemination[1][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-structural protein 1 (flavivirus) (NS1).